Medicare Enrolled
Dr. Amanullah Vazir, MD
Pulmonary Disease · Woodland Park, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Vazir from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vazir?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vazir
Dr. Amanullah Vazir is a pulmonary disease specialist in Woodland Park, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Vazir performed 3,259 Medicare services across 1,544 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vazir received a total of $3,042 from 25 pharmaceutical and/or device companies across 138 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vazir is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 14% volume in NJ
$3,042 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,259
Medicare services
Top 14% in NJ for pulmonary disease
1,544
Unique beneficiaries
$97
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~172 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,229 | $106 | $240 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
573 | $101 | $230 |
| Albuterol inhalation solution, 1 mg A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation. |
303 | $0 | $9 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
232 | $180 | $485 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
220 | $34 | $197 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
145 | $138 | $365 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
113 | $60 | $230 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
77 | $141 | $443 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
50 | $9 | $20 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
42 | $11 | $70 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
41 | $63 | $160 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
38 | $70 | $165 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
32 | $34 | $70 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
27 | $50 | $196 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
26 | $587 | $1,177 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
25 | $52 | $199 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
25 | $155 | $325 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 24 | $20 | $30 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
24 | $485 | $1,246 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
13 | $156 | $365 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$3,042
Total received (2018-2024)
Avg $435/year across 7 years
Top 42% in NJ for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
25
Companies
138
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,635 (86.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$407 (13.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,358
2023
$1,110
2022
$406
2021
$19
2020
$15
2019
$111
2018
$24
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$433
GlaxoSmithKline, LLC.
$202
GENZYME CORPORATION
$199
SANOFI-AVENTIS U.S. LLC
$148
Actelion Pharmaceuticals US, Inc.
$127
Mylan Specialty L.P.
$50
Avadel CNS Pharmaceuticals, LLC
$47
Axsome Therapeutics, Inc.
$31
Amgen Inc.
$29
PFIZER INC.
$23
Resmed Corp
$22
Insmed, Inc.
$18
Gilead Sciences, Inc.
$14
Philips North America LLC
$14
Top 3 companies account for 61.4% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$807
GlaxoSmithKline, LLC.
$590
GENZYME CORPORATION
$228
Actelion Pharmaceuticals US, Inc.
$226
ZOLL Respicardia, Inc.
$189
Mylan Specialty L.P.
$149
SANOFI-AVENTIS U.S. LLC
$148
Axsome Therapeutics, Inc.
$94
Amgen Inc.
$88
Boehringer Ingelheim Pharmaceuticals, Inc.
$72
Insmed, Inc.
$65
Grifols USA, LLC
$60
Avadel CNS Pharmaceuticals, LLC
$47
Philips Electronics North America Corporation
$37
Inogen, Inc.
$35
Nobel Biocare USA
$30
Horizon Therapeutics plc
$28
Medtronic, Inc.
$25
PFIZER INC.
$23
Resmed Corp
$22
CSL Behring
$19
United Therapeutics Corporation
$18
Gilead Sciences, Inc.
$14
Philips North America LLC
$14
Sunovion Pharmaceuticals Inc.
$13
Top 3 companies account for 53.4% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · AIRSENSE · AIRSUPRA · AREXVY · Arikayce · BREO · BREZTRI · BROVANA · DUPIXENT · FASENRA · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INPEN SMART INSULIN DELIVERY SYSTEM · Kcentra · LUMRYZ · NOBELPARALLEL · NUCALA · OPSUMIT · ORENITRAM · PREVNAR 20 · Perforomist · Prolastin-C Liquid · RAYOS · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · Veklury · YUPELRI · Yupelri · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
584
Per 100K population
112.7
County median income
$87,137
Nearest hospital
ESSEX COUNTY HOSPITAL CENTER
2.1 mi
2.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Vazir is a clinical cardiology specialist, with above-average Medicare volume (top 14% in NJ), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Vazir experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Vazir performed 1,229 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vazir receive payments from pharmaceutical companies?
Yes. Dr. Vazir received a total of $3,042 from 25 companies across 138 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vazir's costs compare to other pulmonary diseases in Woodland Park?
Dr. Vazir's average Medicare payment per service is $97. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vazir) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Woodland Park
Browse pulmonary diseases in Woodland Park ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NJ
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NJ
Which NJ pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology